Drug Profile

Research programme: Natural killer cell therapies - ImmuneBridge

Latest Information Update: 15 Jan 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ImmuneBridge
Class Antineoplastics; Immunotherapies; NKT cell therapies
Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

22 Nov 2023 Research programme: Natural killer cell therapies - ImmuneBridge is available for licensing as of 22 Nov 2023. https://www.immunebridge.com/science (ImmuneBridge website, November 2023)
11 Apr 2023 Early research in Haematological malignancies in USA (Parenteral) prior to April 2023
11 Apr 2023 Early research in Solid tumours in USA (Parenteral) prior to April 2023

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com